Treatment with olorofim demonstrates noninferiority to AmBisome-based standard of care (SOC) for the treatment of invasive aspergillosis (IA) in patients for whom a mold-active azole antifungal (MAA) is either inappropriate or ineffective, according to a study.
“Olorofim was noninferior to AmBisome-based SOC for day 42 all-cause mortality, [the primary endpoint],” said study co-author and presenter Dr John Rex, chief medical officer, F2G, Princeton, New Jersey, US. “Olorofim was [also] well tolerated, [with] treatment-emergent adverse events (TEAEs) [being] less frequent than for AmBisome-based SOC.”
Rex and his team conducted this randomized, controlled, adjudicator-blinded trial in adults with proven IA or probable IA for whom MAA was inappropriate. Patients with IA diagnosed 4 days prior were enrolled for known/suspected azole resistance, MAA prophylaxis breakthrough, or drug-drug interactions, and those with MAA for 8‒28 days were enrolled for failure of initial MAA therapy.
Between 29 April 2022 and 18 November 2025, a total of 225 patients were randomized 2:1 to receive up to 84 days of either oral olorofim (150 mg BID on day 1 then 90 mg BID; n=151) or intravenous AmBisome (3 mg/kg QD) for at least 10 days, followed by SOC antifungals (n=74). All-cause mortality at day 42 in the intention-to-treat population was the primary endpoint.
Olorofim met the primary endpoint of noninferiority to AmBisome-based SOC (day 42 all-cause mortality: 23.8 percent vs 24.3 percent; difference, ‒0.5 percent, 95 percent confidence interval, ‒13.1 to 10.8). [Rex, J, et al, IDWeek 2026]
Global success
Likewise, day 84 all-cause mortality (32.5 percent vs 29.7 percent) and blinded Data Review Committee (DRC)-adjudicated Mycoses Study Group (MSG) and the European Organization for Research and Treatment of Cancer (EORTC) global success at end of therapy (31.8 percent vs 32.4 percent) did not significantly differ between the two treatment groups.
“The MSG-EORTC global response is a composite of clinical, radiological, and mycological responses,” Rex said. “Global success requires all three subcomponents to improve.”
In the study, the DRC-adjudicated responses were similar between olorofim and AmBisome-based SOC (clinical: 57 percent vs 54 percent; radiological: 43 percent vs 35 percent; mycological: 37 percent vs 34 percent; global response: 48 percent vs 45 percent).
Safety profile
In the olorofim group, no new safety signals were observed. Overall (96.0 percent vs 94.4 percent) and serious TEAEs (68.9 percent vs 66.7 percent) did not significantly differ between groups. However, drug-related TEAEs (35.8 percent vs 63.9 percent) and serious drug-related TEAEs (4.0 percent vs 18.1 percent) occurred less frequently with olorofim.
The difference in drug-related TEAEs was driven primarily by renal events, with two in the olorofim group compared with 16 in the AmBisome-based SOC group (1.3 percent vs 22.2 percent). The incidence of related hepatobiliary TEAEs was low and similar between groups (2.0 percent vs 4.2 percent).
“Hepatic toxicity is a safety risk for olorofim and requires biochemical monitoring,” Rex said.
“These data support olorofim as an oral treatment option for IA when a mold-active azole is inappropriate or ineffective,” he added.
MAAs, the preferred therapy for IA, can be inappropriate for some patients due to azole resistance, breakthroughs on azole prophylaxis, drug-drug interactions, intolerance, or initial MAA failure, according to Rex, noting that a lipid-associated amphotericin B-based regimen in currently the recommended initial alternative therapy.
“Olorofim, a novel orotomide antifungal, blocks pyrimidine biosynthesis and kills Aspergillus spp. and related mold fungi by selectively inhibiting fungal dihydroorotate dehydrogenase,” he said.